Cash and cash equivalents as of December 31, 2023, were approximately $76.3 million. The company believes its cash and cash equivalents, together with the development milestone payments due under its license agreement with GSK, will be sufficient to fund anticipated operating and capital expenditure requirements into late 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SPRO:
- Spero Therapeutics Provides Corporate Update and 2024 Outlook
- Spero announces first patient, first visit for Phase 3 PIVOT-PO trial
- Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections
- Spero Therapeutics reports Q3 EPS (6c), consensus (3c)
- Is SPRO a Buy, Before Earnings?
